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Steff Lewis5, Michael Eddleston3,4, Simon HL Thomas1 and D Nicholas Bateman4*
Abstract
Background: Paracetamol (acetaminophen) poisoning remains the commonest cause of acute liver injury in Europe
and North America. The intravenous (IV) N-acetylcysteine (NAC) regimen introduced in the 1970s has continued
effectively unchanged. This involves 3 different infusion regimens (dose and time) lasting over 20 hours. The same
weight-related dose of NAC is used irrespective of paracetamol dose. Complications include frequent nausea and
vomiting, anaphylactoid reactions and dosing errors. We designed a randomised controlled study investigating the
efficacy of antiemetic pre-treatment (ondansetron) using standard NAC and a modified, shorter, regimen.
Methods/Design: We designed a double-blind trial using a 2 × 2 factorial design involving four parallel groups. Pre-
treatment with ondansetron 4 mg IV was compared against placebo on nausea and vomiting following the standard
(20.25 h) regimen, or a novel 12 h NAC regimen in paracetamol poisoning. Each delivered 300 mg/kg bodyweight
NAC. Randomisation was stratified on: paracetamol dose, perceived risk factors, and time to presentation. The primary
outcome was the incidence of nausea and vomiting following NAC. In addition the frequency of anaphylactoid
reactions and end of treatment liver function documented. Where clinically necessary further doses of NAC were
administered as per standard UK protocols at the end of the first antidote course.
Discussion: This study is primarily designed to test the efficacy of prophylactic anti-emetic therapy with ondansetron, but
is the first attempt to formally examine new methods of administering IV NAC in paracetamol overdose. We anticipate,
from volunteer studies, that nausea and vomiting will be less frequent with the new NAC regimen. In addition as
anaphylactoid response appears related to plasma concentrations of both NAC and paracetamol anaphylactoid reactions
should be less likely. This study is not powered to assess the relative efficacy of the two NAC regimens, however it will
give useful information to power future studies. As the first formal randomised clinical trial in this patient group in over
30 years this study will also provide information to support further studies in patients in paracetamol overdose,
particularly, when linked with modern novel biomarkers of liver damage, patients at different toxicity risk.
Trial registration: EudraCT number 2009-017800-10, ClinicalTrials.gov Identifier NCT01050270
Keywords: Paracetamol, Acetylcysteine, Overdose, Antidotes, Hepatotoxicity
Background
Paracetamol (acetaminophen) is the commonest agent
taken in overdose in the UK. Paracetamol poisoning had a
significant mortality (5–6%) and major morbidity (58%)
prior to the introduction of antidotal therapy [1-3]. For
example, in a cohort of 57 untreated patients hospitalised
with paracetamol overdose, 33 (58%) developed severe he-
patocellular injury and 3 (5%) died [2].
After paracetamol overdose, the normal metabolic path-
ways via sulphation and glucuronidation become saturated,
leading to increased formation of the reactive intermediate
metabolite, N-acetyl-p-benzoquinoneimine (NAPQI). Small
amounts of NAPQI produced during therapeutic parace-
tamol use can be detoxified safely in glutathione-dependent
reactions, but after overdose formation of NAPQI outstrips
availability of glutathione, resulting in covalent binding of
NAPQI to hepatocytes, culminating in cell death. Thus,
without treatment paracetamol overdose can cause hepa-* Correspondence: spib@luht.scot.nhs.uk
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tocellular injury leading to fulminant hepatic failure and
death.
Antidotes for paracetamol poisoning that act by
replenishing hepatic glutathione were developed in the
1970s. In the UK, the intravenous N-acetylcysteine
(NAC) regimen developed by Prescott and colleagues in
Edinburgh has transformed the management of para-
cetamol poisoning, with liver function abnormalities
much less common in treated patients than in untreated
historical controls. Despite the complexity of this regi-
men, involving three different infusions over a 20.25 h
period [2], it has been used routinely in the management
of paracetamol overdose for over 30 years.
In the USA the lack of an approved NAC preparation
for intravenous use led to the development of a 3-day
oral NAC regimen [4]. This was used widely and it is
only over the past decade there has been a general
change to the shorter intravenous NAC regimen in the
USA, after its approval by the US Food and Drug Ad-
ministration (FDA) in 2004.
Neither the oral or intravenous NAC regimens have
been subject to formal comparative trials, NAC doses
were largely empiric and not subject to more precise
dose refinement. NAC dosing is determined on the basis
of patient weight for all patients in whom treatment is
deemed indicated, irrespective of the ingested dose of
paracetamol.
Although highly effective, especially if started within a
few hours of paracetamol overdose, the current licensed
intravenous NAC regimen has several disadvantages.
Firstly, intravenous NAC is commonly associated with
adverse effects, the most common being nausea, vo-
miting and anaphylactoid reactions [5-7]. Anaphylactoid
reactions appear related to the rate of infusion of NAC
and its concentration in blood. Thus they are most com-
mon during, or soon after, the initial high dose infusion.
A previous study, however, failed to show that pro-
longing the initial 15 min infusion to one hour signifi-
cantly alters their incidence [8]. It is also important to
note that anaphylactoid reactions appear more com-
mon in patients with lower paracetamol concentrations
[7,9,10]. Secondly, the infusion schedule is complex, re-
quiring prescription of three different infusions, and this
contributes to a high risk of medication errors [11-13],
which may have serious, potentially life-threatening, ad-
verse outcomes [14,15].
Thirdly, the required duration of the infusion regimen
results in prolonged hospital stay, especially as patients
with paracetamol overdose often present during the
night. Since it is difficult to discharge patients after
22.00 and before 08.00, currently any patient presenting
between 20:00 and 08:00 is likely to spend a second
night in hospital if NAC is administered over 20.25 h
and bloods are checked at end of treatment. This
effectively means that any patient in whom NAC therapy
is commenced is likely to be in hospital well over
24 hours, despite the majority never developing any
evidence of liver injury. With a shorter infusion regimen,
e.g. over 12 h, patients presenting at any time before
08:00 could potentially be discharged before 22.00, thus
reducing the length of hospital stay for a significant
proportion of patients. Based on our clinical experience
in Edinburgh and Newcastle we estimate that more than
40% of hospital bed occupancy due to paracetamol
overdose is due to treatment with NAC. Applying this to
the UK, it would amount to 32,000 bed-days/year. We
estimate that use of a shorter-duration regimen may
potentially save more than 10,000 bed-days per annum
across the UK.
We hypothesised that it should be possible to design
an alternative method for administering NAC, in which
the antidote was delivered using a simpler regimen and
for a shorter time, while still providing adequate plasma
concentrations of acetylcysteine for liver protection. We
approached funders with the view to conducting an ini-
tial study of a new modified NAC regimen in patients
with paracetamol poisoning. They indicated it would be
necessary to do a smaller preliminary study focused on
measuring rates of adverse reactions with both regimens,
before a larger formal clinical trial of efficacy could be
considered. Since no clinical trial had been done in acute
paracetamol poisoning in the UK since the 1970s, they
also stressed the importance of assessing the practi-
calities of such a study if a new dose regimen, or pos-
sibly even new antidotes, were to be developed. We
therefore decided to focus on antiemetic prophylaxis of
patients receiving NAC as this is the commonest adverse
effect [5-7]. We designed a factorial study in which we
compared the antiemetic efficacy of ondansetron with
placebo in patients who received standard, or a new mo-
dified regimen of NAC. This manuscript describes the
methodologies of this study.
Methods
The study, EudraCT number 2009-017800-10, Clinical-
Trials.gov Identifier NCT01050270, was funded by the
Scottish Chief Scientist Office (grant no CZB/4/722), ap-
proved by the MHRA, the Scotland A Research Ethics
Committee, UK (ref no 10/MRE00/20) and sponsored by
the University of Edinburgh and NHS Lothian ACCORD
Governance & QA Office.
The trial design was developed as a multi-centre study
involving 2 acute clinical toxicology units in the Royal
Infirmary of Edinburgh and the Royal Victoria Infirmary
of Newcastle upon Tyne. A third unit in Aberdeen Royal
Infirmary agreed to join the study to achieve adequate
patient recruitment within the trial timeframe. The study
was primarily designed to test the efficacy of prophylactic
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antiemetic therapy with ondansetron but was also de-
signed to assess the impact of a new NAC infusion regi-
men therapy on incidence of adverse effects. A third aim
was for the study to provide sufficient experience and data
to assess the feasibility of and adequately design and
power a study of the modified NAC regimen as a new
treatment for this common form of poisoning, as this has
a major potential to both reduce patient adverse events
from NAC therapy and shorten duration of hospital stay.
Study design
The trial was conducted using a 2X2 factorial design in-
volving 4 parallel groups with the following treatment al-
locations (Table 1):
i. Pre-treatment with antiemetic (ondansetron 4 mg
IV) compared to matched placebo in a double blind
fashion.
ii. Conventional acetylcysteine regimen (300 mg/kg
over 20.25 h as: 150 mg/kg in 200 mL over 15 min,
then 50 mg/kg in 500 mL over 4 h, then 100 mg/kg
in 1000 mL over 16 h) compared to a modified 12 h
acetylcysteine regimen (300 mg/kg over 12 h as:
100 mg/kg in 200 mL over 2 h, then 200 mg/kg in
1000 mL over 10 h, followed by 5% glucose over 8 h).
Rationale for study drugs and doses
i) Ondansetron pre-treatment
It is unclear why no attempt has been made to test
antiemetic pre-treatment in the setting of
acetylcysteine administration, as only a few other
treatments such as cytotoxic chemotherapy are
associated with such a high reported rate of nausea
and vomiting.
Ondansetron is an antagonist at 5HT3 receptors in
the gastrointestinal tract and central nervous system.
The licensed indications include prevention of post-
operative nausea and vomiting (standard dose 4 mg
at induction of anaesthesia) and treatment or
prophylaxis of nausea and vomiting with emetogenic
cytotoxic chemotherapy (standard dose 8 mg) [16].
It has been shown to be effective in both settings
[17] and has a well-characterised adverse effect
profile [16]. Common adverse effects include
headache, flushing and constipation. Very rarely,
hypersensitivity reactions, transient ECG changes
(including QT prolongation) and seizures have been
reported [16].
Although more expensive than alternative
antiemetics such as cyclizine or metoclopramide,
ondansetron was chosen for the following reasons:
i) it is the most frequently used licensed drug for
the prophylactic treatment of post-operative
nausea and vomiting (PONV) and chemotherapy-
induced vomiting;
ii) there is considerably more randomised controlled
trial evidence supporting ondansetron for this
prophylactic use compared to other older and
less expensive alternatives [18];
iii) anti-dopaminergic agents such as
metoclopramide may cause dystonic reactions,
particularly in the younger age group likely to be
represented in this trial;
iv) cyclizine has anti-histaminergic activity. Since one
of the aims of this study was to examine the
effect of the modified NAC regimen on rates of
histamine-mediated anaphylactoid reactions it
was felt that the use of cyclizine could have led to
an interaction between the antiemetic and the
rates or severity of anaphylactoid reactions in this
study. This would thus make power calculations
for future studies more difficult.
With regards to the choice of dose, one randomised
double-blind dose–response study using six different
ondansetron doses (0.5–8 mg) showed that 4 mg
was the optimal prophylactic dose and was only
barely superior to lower doses [19]. A systematic
review of ondansetron in the treatment of PONV
also found no differences in efficacy when 1, 4 or
8 mg ondansetron were used [20]. These studies do
not support the use of the higher 8 mg dose. The
mechanism of nausea and vomiting following
paracetamol overdose is not clearly defined but is
likely to be multi-factorial, a situation comparable to
that of PONV. Nausea and vomiting following
paracetamol overdose, although common, is usually
not as severe or protracted as after chemotherapy.
We, therefore, considered that an antiemetic
prophylactic ondansetron dose lower than that used
for chemotherapy-induced vomiting and similar to
that used for PONV would be appropriate.
For rescue medication the antihistamine cyclizine
was chosen as this was significantly better than a
repeat 4 mg dose of ondansetron (complete response
78% vs. 46%) in PONV [21]. Also, in a randomised
clinical trial of repeat 4 mg ondansetron dose rescue
Table 1 Drug treatment groups
Ondansetron 4 mg IV
Pre-Treatment
Placebo IV Pre-Treatment
Conventional acetylcysteine
regimen
Conventional acetylcysteine
regimen
Ondansetron 4 mg IV
Pre-Treatment
Placebo IV Pre-Treatment
Modified 12 h acetylcysteine
regimen
Modified 12 h acetylcysteine
regimen
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therapy vs. placebo, ondansetron was no better than
placebo at controlling PONV [22]. Based on these
studies in PONV, we chose an initial dose of 4 mg
ondansetron, which is the licensed and effective dose
of ondansetron for PONV with intravenous cyclizine
50 mg used as rescue therapy for those with
continuing symptoms.
ii) Acetylcysteine infusion regimen
We consider that if it were possible to use a 12 h
infusion of NAC it could significantly reduce
hospital stay. There is also evidence suggesting that
high concentrations of NAC following the initial
loading infusion in the Prescott regimen are likely
related to the incidence of adverse drug reactions
(ADRs) [7]. Using pharmacokinetic data derived
from Prescott [23], we performed a Monte Carlo
simulation to derive expected plasma
concentrations, based on a 1-compartment model,
using a new shorter 300 mg/kg NAC regimen. This
consisted of a two hour infusion of 100 mg/kg
followed by ten hours of 200 mg/kg, both in 5%
dextrose. Applying this we estimated that the
modified infusion regimen would give rise to a mean
plasma concentrations of 306, 122 and 30 mg/L at
2 h, 12 h and 20 h respectively and that the
probability that the peak plasma acetylcysteine
concentration at the end of the 2 h loading infusion
would be greater than 150 mg/L and less than
650 mg/L was greater than 99%. This regimen would
therefore administer the same total dose of NAC but
achieve a lower peak and a 20 h plasma concentration
comparable to the conventional regimen (Figure 1)
[23]. In preliminary studies in healthy volunteers
examining the effects of the modified NAC regimen
on renal function, plasma concentration data was in
line with these predictions [24].
Assuming that anaphylactoid reactions to
acetylcysteine are concentration-related and that this
occurs in patients who achieve a peak concentration
more than 1 standard deviation above the mean
(based on the observation that about 15% of patients
develop such reactions [8], the pharmacokinetic data
with the conventional regimen suggest that these
reactions occur at concentrations of greater than
650 mg/L. Simulated data using the proposed
modified regimen suggest that <1% of patients
would achieve an NAC concentration of >650 mg/L,
therefore, potentially leading to a marked reduction
in the incidence of anaphylactoid reactions.
Preliminary data from healthy volunteers and
patients in a clinical trial using the new NAC
regimen as prophylaxis against contrast-induced
liver injury, has found that nausea or vomiting have
not occurred [24], suggesting that acute adverse
effects will be less common with this new regimen
in patients who receive it for paracetamol poisoning.
In order to approximately match fluid regimens
between conventional and modified regimens, the
modified regimen included a terminal 8 h 5%
dextrose infusion (Table 1).
Identifying patients
Potentially eligible patients were identified by treating
clinicians at the Emergency Departments of the Royal
Infirmary of Edinburgh; the Medical Assessment Unit
and the Emergency Department the Royal Victoria In-
firmary, Newcastle; and the Emergency Department of
Estimated NAC concentrations 
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Figure 1 Monte Carlo calculations of proposed modified acetylcysteine regimen.
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Aberdeen Royal Infirmary. A trained member of staff
then assessed the patient for study eligibility.
Patients were deemed eligible for consideration if they
presented to the relevant acute units within 36 hours of
a single acute paracetamol overdose and required treat-
ment with NAC, based on standard UK guidance for
management as published on TOXBASE and in the Brit-
ish National Formulary. The decision to treat depends
on the paracetamol concentration in relation to the time
since ingestion and is interpreted using a treatment
nomogram. Until Sept 2012 treatment was indicated for
patients without additional risk factors for paracetamol
hepatotoxicity presenting with a timed paracetamol con-
centration above a line commencing at 200 mg/L at 4 h
after overdose and falling exponentially with a half-life
of 4 h (the ‘200’ line). For patients with at least one risk
factor, treatment was indicated at concentrations 50%
lower than this, i.e. above a ‘100’ treatment line [25].
Risk factors were defined as follows in two categories:
a) Nutritional deficiency, malnourished and/or
debilitating disease: acute or chronic starvation,
eating disorders, cachexia, malabsorption
syndromes, AIDS, cystic fibrosis, hepatitis C,
chronic alcoholism.
b) Enzyme induction: use of drugs with this property
(carbamazepine, rifampicin, barbiturates, phenytoin,
rifabutin, efavirenz, nevirapine, St John’s Wort);
regular consumption of ethanol above advised
amounts.
For patients presenting more than eight hours after in-
gestion, and at risk of liver damage based on history of
dose ingested, treatment with acetylcysteine is started
immediately pending the results of plasma paracetamol
concentration measurement. For those presenting within
8 h, current recommendations are to wait for results of
plasma paracetamol concentration measurement before
starting NAC. After Sept 2012 the trial was modified in
line with new UK guidance on management of paraceta-
mol poisoning (see below).
Trial exclusions
The following exclusion criteria were applied throughout
the trial:
patients less than 16 years old; those detained under
the Mental Health Act; those with known permanent
cognitive impairment; patients with a life-threatening ill-
ness; patients known to be pregnant; those who had pre-
viously participated in the study; those considered to
have an unreliable history of paracetamol overdose; pa-
tients presenting more than 36 hours after overdose
(24 h up to May 2011) of a single acute paracetamol
overdose; patients presenting after taking a staggered
paracetamol overdose (defined as when the overdose of
paracetamol was taken over a period of more than 2 h
(1 h up May 2011); patients taking anticoagulants
(e.g. warfarin) in therapeutic doses or in overdose; pa-
tients who, in the opinion of the responsible clinician/
nurse, were unlikely to complete the full course of NAC
e.g. expressing wish to self-discharge: patients who in
the opinion of the responsible clinician/nurse were
unable to complete the initial questionnaire either them-
selves or with nurse assistance; a history of hypersen-
sitivity to 5HT3 antagonists; non-English speaking
patients. Trial information material was only produced
in English in view of the known and stable demographic
of the Edinburgh, Newcastle and Aberdeen self harm
population.
Data collection
The following data were collected at baseline prior to
randomisation: Patient demographics (age and gender);
height and weight; screening and eligibility criteria; pa-
racetamol poisoning information including risk as-
sessment; co-ingestion of other drugs or ethanol. This
information was collected directly onto a patient recruit-
ment and randomisation forms, and undertaken by dele-
gated trained clinical or research staff.
Consent was taken prior to randomization by delegated
trained clinical staff and recorded on a consent form in
triplicate, with one copy given to the participant; one
placed in the research files and one kept in the hospital
notes.
Study treatment information was collected during the
treatment phase and recorded on the Case Report Form by
trained clinical or research staff. Adverse reactions (at base-
line, 2 h and 12 h) - were measured via an 11-point Likert
scale (whereby 0 = none, 10 = very severe) on the following
9 symptoms. This was a self-assessment done by the pa-
tient (or completed by the nurse if the patient was phy-
sically unable to complete the form) and completed as a
questionnaire.
 Nausea
 Feeling flushed
 Itchy skin
 Skin rash
 Chest pain
 Headache
 Feeling breathless
 Feeling wheezy
 Tongue/lip swelling
In addition episodes of vomiting and retching were
recorded objectively by nursing staff at baseline, and at
2 h and 12 h after initiation of acetylcysteine.
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Blood samples for paracetamol concentration, INR,
urea and electrolytes (U&Es), creatinine, full blood count
(FBC) and liver function tests including ALT, bilirubin
and gamma glutamyl transferase (GGT) were obtained
at baseline and at 12 h and 20.25 h after initiation of
acetylcysteine. These samples were taken by clinical staff.
Results were collected by the research team, via the hos-
pital electronic laboratory reporting system.
Blood pressure and pulse were recorded at the follow-
ing time points: 0 h, 15 min, 2 h, 4 h, 12 h and 20.25 h
(end of treatment).
Any use of rescue medication was recorded contem-
poraneously in the Case Report Form by clinical staff.
Any other clinical features were also collected from the
clinical records.
Novel biomarker substudy
Each time a blood sample was taken in the main study
or pharmacokinetic sub study, 2 additional samples were
obtained for the measurement of the proteomic and in-
flammatory response to paracetamol poisoning.
Pharmacokinetic substudy
Acetylcysteine concentrations were measured in a con-
venience sample of patients in Edinburgh. It was agreed
that samples could be obtained at any of the potential
time points in consenting patients; baseline, 15 mins,
2 h, 4 h or 12 h and end of treatment. These samples
were taken by nominated research staff and stored for
subsequent analysis.
Discharge
Outcome and survival data were collected by the re-
search team via the hospital electronic system and clini-
cal notes, and recorded in the Case Report Form.
Adverse events
These were monitored and recorded contemporaneously
in the Case Report Form by clinical staff, consistent with
the sponsor’s quality and assurance processes. These were
monitored as agreed by a Data Monitoring Committee
comprising Prof RE Ferner (Clinical Pharmacologist,
Birmingham, Chair), Dr K Simpson (Hepatologist,
Edinburgh) and Dr J E Gray (Statistician, Leeds).
Data for analysis
All data was entered onto a purpose built web-based
database to be analysed within the Edinburgh Clinical
Trials Unit.
Consent process
The trial was undertaken in accordance with the Medi-
cine for Human Use (Clinical Trials) Regulations 2004
and all subsequent amendments. The main ethical chal-
lenge was that potential participants were acutely ill and
may initially have lacked capacity to provide informed
consent, or the ability to complete a written consent
form, yet the very nature of the trial required that re-
cruitment took place quickly in an emergency and in-
cluded acutely ill patients.
Patients (and if present and appropriate their accom-
panying relative) were provided with a Summary Patient
Information Sheet, and given time to consider the trial
and ask questions regarding their participation. They
were interviewed by a delegated recruiting doctor, mid-
dle grade or above, who had completed GCP training,
including specific training in assessing capacity. Potential
participants were given further verbal information before
being asked to provide written witnessed consent.
Potential participants who were able to express con-
sent, but unable to complete the consent form, were
recorded as having provided verbal witnessed consent.
Subsequent written consent for continuation in the trial
was sought as soon as possible after recruitment. In the
event of a patient refusing consent at this point, the pa-
tient was withdrawn and no further data collected, but
the patient’s permission was sought to use the data col-
lected up to that point. If the patient objected to this, all
data collected for the patient was destroyed. All patients
were, however, strongly advised to complete their treat-
ment in order to protect their liver from paracetamol toxi-
city. As soon as the patient’s condition allowed they were
provided with the Full Patient Information sheet (as soon
as possible after the initial emergency has passed).
While a majority of patients were able to provide
witnessed written or verbal consent, a minority lacked
initial capacity to consent because of reduced conscious
level or cognitive impairment. In those where loss of
capacity was deemed to be temporary e.g. alcohol or
drug intoxication, consent was sought after discussion
and agreement from a relative Figure 2.
Randomisation process
Randomisation was performed via a web-based randomi-
sation service, managed by the Edinburgh Clinical Trials
Unit, after a delegated recruiting doctor had assessed a sub-
ject as meeting the eligibility criteria. Baseline data entered
on to the system were stored securely and the treatment
allocation was provided. Once a patient was randomised
he/she remained in the study and had all outcomes re-
corded regardless of compliance with medication, unless
he/she specifically withdrew consent to have data stored.
A minimisation program, including a random element,
was used to achieve optimum balance for the most im-
portant prognostic factors:
 Time from ingestion to treatment dichotomised as
<8 h and 8–24 (later 36) h.
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 Presence of any, vs. absence of all of the risk factors.
 Reported paracetamol dose, dichotomised as <16 g
and >16 g.
This minimisation program was applied independently
at all recruitment sites to try to ensure balance across sites.
It was not changed after the MHRA advice of September
2012, which reduced threshold for treatment to the
“100 mg” line, although it was expected that a conse-
quently higher proportion of “low risk” patients would be
recruited in the final weeks of the trial.
All participants, the medical and nursing staff caring for
them and the research teams were blinded to the antie-
metic treatment allocation. Patient packs, specially pre-
pared and packaged for clinical trial purposes, containing
closely matched ondansetron (2 mg/mL) and placebo
(0.9% saline) 2 mL ampoules were prepared and labelled
to patient allocation number to reduce the chance of code
break. Stores of packs were held within the hospital phar-
macy and sufficient packs supplied as required.
Doses of NAC were based on the patient’s weight and
therefore infusions need to be prepared individually for
each patient. As a result it was not feasible for patients,
clinicians or researchers to be blinded to treatment allo-
cation. The infusions were designed to run over 20.25 h
in both treatment arms to make the treatment allocation
less obvious and patients were not told which treatment
they have been assigned to.
Treatment allocation was on a 1:1:1:1 ratio across the
4 parallel drug treatment groups.
          1.  Assess capacity 
2.  Patient has capacity  to give 
informed consent 
3.  Patient does NOT have 
capacity  to give informed 
consent 
Patient is ABLE  to sign 
consent form 
Patient is NOT able to 
sign consent form 
Witnessed written 
consent 
Witnessed verbal 
consent 
4.  Is lack of capacity 
considered temporary 
(expected to last <12h) e.g. 
YES NO
Witnessed written consent as 
soon as practicable after initial 
emergency has passed  
Do Not              
Randomise 
Patient accompanied by a personal 
legal representative? 
Yes No
Seek consent from personal legal 
representative then seek further 
consent from patient as soon as 
patient regains capacity 
Figure 2 Consent flowchart.
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Substantial amendments to trial protocol
The trial commenced in September 2010 and since
that date 2 major protocol amendments have been
made.
i) Recruitment was initially extremely slow and we
identified definition of “staggered” overdose as the
reason for this. The initial study defined a
“staggered” overdose as ingestion over 1 h or more.
We soon became aware that in reality a substantial
proportion of patients consumed their tablets over a
longer period than 1 h.
The protocol was therefore amended after
discussion between the investigators, the DMC,
the Ethics Committee and the Sponsor. From
May 2011 eligibility criteria changed to include
patients who had taken an overdose over a period
of less than 2 h (previously 1 h). In addition the
maximum time after overdose that patients could
be included in the trial was increased from 24
to 36 h.
ii) A second more radical change occurred in
September 2012, when on the advice of the UK
Commission on Human Medicines (CHM) the
MHRA published new guidelines for the
management of acute paracetamol poisoning.
These recommended use of a single ‘100’
nomogram treatment line for all patients. They
also recommended that risk factors should no
longer be taken into account when considering
the need for acetylcysteine. After discussion with
the investigators, MHRA clinical trials unit, the
Ethics Committee and the Trial Data Monitoring
Group this new treatment limit was adopted in
the trial as from 6th Sep 2012. We did not,
however, change our approach to dosing with
NAC, in particular there was no change in the
rate of infusion in the standard therapy group,
although CHM and MHRA had recommended a
longer (1 h) duration for the initial 150 mg/kg
acetylcysteine infusion.
Events and outcomes
Primary objective
To determine whether pre-treatment with intravenous
ondansetron 4 mg reduces the occurrence of retching or
vomiting in paracetamol poisoned patients receiving
intravenous acetylcysteine. Retching was defined as an
attempt to vomit not producing any liquid. The pri-
mary endpoint was the proportion of patients in each
group who do not vomit or retch within 2 hours of ini-
tiation of NAC treatment and had no use of rescue
medication.
Secondary objectives
1) To determine whether pre-treatment with
intravenous ondansetron 4 mg will reduce the
occurrence of nausea in paracetamol poisoned
patients receiving intravenous NAC within 12 h of
initiation of that treatment. Nausea severity was
assessed using an 11–point, whole number,
categorical Likert scale, with 0 representing “no
nausea” and 10 representing nausea “as bad as it can
possibly be” [26,27]. Patients were deemed to have
failed to have adequate control of nausea if they had
a score of greater than 4 at any time up to 12 h after
commencement of NAC or if they received rescue
medication [27].
Additional data collected will inform the design of
future clinical studies, although this study is not
powered to detect differences in efficacy or safety
between the two NAC infusion regimens:
2) To compare the incidence of anaphylactoid reactions
in the modified and conventional NAC regimens in
paracetamol poisoned patients. This is to be derived
from the case records, need for treatment of an
anaphylactoid response and self-reported incidence of
flushing, itchy skin, skin rash, chest pain, feeling
breathless, feeling wheezy and tongue/lip swelling on
the Likert scales and documented changes in blood
pressure and pulse rate.
Symptom data is collected on 11-point Likert scales
with upper and lower descriptors of “none” and
“very severe” at baseline, 2 and 12 h. A score of 5 or
over will be taken to represent a positive feature on
each scale. The domains the scales cover are as
follows:
Skin features
 Feeling flushed
 Itchy skin
 Skin rash
Respiratory
 Feeling breathless
 Feeling wheezy
Systemic features
 Tongue/lip swelling
 Chest pain
 Change in BP and pulse
A positive score within a domain of skin, respiratory
or systemic, will be used to indicate a response in
the grading assessment of anaphylactoid response
described below. A fall in systolic pressure of
20 mmHg or more, or rise in pulse rate of 20 bpm
or more will be taken as positive features of an
anaphylactoid response.
In addition we will have access to data on blood
pressure and pulse rate change at 15 min, 4 hours
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post commencement of infusion, and these are the
times when anaphylactoid responses to NAC are
most likely.
Anaphylactoid reaction severity will be assessed on a
3-grade severity scale, based on the World Allergy
Organization guidelines (2011) [28].
Grade 1. The least severe group would be patients
who only had a positive response in one of the
domains on the Likert scales, or change in blood
pressure or pulse rate as defined above.
Grade 2. The intermediate grading would be
patients who had positive responses in 2 or more
symptom domains on the Likert scales, and/or
cardiovascular change measured in blood pressure
or pulse, but did not require cessation of NAC
therapy, or other specific treatments.
Grade 3. The most severe grading would be
patients who had NAC treatment discontinued
and/or an intervention with anti-allergy therapy.
3) To determine the rate of occurrence of
hepatotoxicity in patients treated overall and with
the modified and conventional NAC administration
regimens. These to be determined as:
a) Proportion of patients with a 50% increase in
ALT after 20.25 h post-treatment with NAC,
compared with the admission value overall, in
each treatment arm, and in those receiving the
different NAC regimens.
b) Proportion of patients with ALT > 1000 at 20.25 h
post-treatment with NAC overall, in each
treatment arm, and in those receiving the
different NAC regimens.
c) Proportion of patients with INR > 1.3 at 20.25 h
post-treatment with NAC overall, in each
treatment arm, and in those receiving the
different NAC regimens.
4) To measure total length of hospital stay in patients
receiving modified and conventional acetylcysteine
treatment regimens.
5) To identify new blood markers for paracetamol-
induced liver injury. These included protein and
RNA markers during both conventional and
modified regimens, in order to find new markers
that identify organ injury earlier in the disease
process than current markers [29]. This is critical
for further development of the modified NAC
regimen as patient stratification and early rule
out of injury are essential as a companion
diagnostic.
6) In addition a convenience subsidiary sample of
patients were collected in a trial subset in
Edinburgh, and had blood samples taken to measure
plasma acetylcysteine concentrations of modified
and conventional regimens.
Statistical analysis
In a Cochrane Database systematic review of antiemetics
used in the prophylaxis of PONV, treatment with prophy-
lactic ondansetron compared to no drug treatment was
associated with a risk ratio of 0.42 (95% CI 0.34–0.52) for
vomiting and a risk ratio of 0.56 (95% CI 0.44–0.72) for
nausea or vomiting.
To achieve at least 80% power to detect a relative risk
of 0.6 for the proportion of patients with retching or
vomiting within 2 hours (from 60% in the treated group
to 36% in the placebo group), 91 patients need to be en-
rolled in each group (significance level set at 0.25 to
allow for 2 comparisons in factorial study). To allow
for a potentially higher drop-outs/non-compliance rate
in this challenging population, in whom a proportion
would be randomized without paracetamol concentra-
tion data available (those >8 h post overdose), we
planned to include 250 patients, 125 patients rando-
mised to ondansetron, and 125 to placebo. This was to
ensure 50 patients in each of the four groups in the fac-
torial study (ondansetron with conventional regimen,
placebo with conventional regimen, ondansetron with
modified regimen and placebo with modified regimen),
and allow for a 20% trial drop out in the analysis of the
primary outcome.
The trial will be analysed for all outcomes on an
intention-to-treat basis, although because of the trial
design, and need to recruit late presenting patients
prior to paracetamol concentration data being available,
some may not achieve the primary endpoint. These pa-
tients therefore cannot be included in an end-point
analysis.
Discussion
Paracetamol is the commonest drug taken in overdose in
the United Kingdom, including in Scotland [30-32]. Hos-
pitalisation due to paracetamol overdose accounted for
approximately 80,000 bed days in the UK in 2005–2006
(source: Hospital Episode Statistics & ISD Scotland). A
substantial proportion of this time results from use
of NAC. Although highly effective in preventing liver
damage if given sufficiently early, further disadvantages
of the conventional intravenous NAC infusion regimen
are the high rates of adverse reactions and the com-
plexity of dosing and resulting high risk of medication
errors.
To address these disadvantages, a modified NAC dose
regimen has been designed to be shorter and simpler
than the conventional regimen and associated with lower
initial plasma concentrations in an attempt to reduce
the incidence of dose-related adverse effects. This modi-
fied regimen administers the same total dose in 2 sepa-
rate infusions instead of 3 and, therefore, may reduce
the risks of error associated with preparing infusions.
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Ideally, such a regimen would be used in routine clinical
practice after an adequately powered efficacy study had
been performed. In theory, the slower initial delivery of
NAC may result in less effective early generation of he-
patic glutathione for detoxification of NAPQI, although
any difference between the current 1 h and proposed
and 2 h regime is likely to be small. Also, the shorter
total duration of the infusion may mean that delivery of
NAC ceases before all NAPQI has been formed and de-
toxified, leaving some patients inadequately treated.
Such patients would be expected to have detectable
paracetamol concentrations at the end of the 12 h infu-
sion and the frequency of this finding is being assessed
in this clinical trial.
Ideally, any efficacy study comparing new and conven-
tional acetylcysteine regimens would need to be powered
to establish non-inferiority. Based on the efficacy of cur-
rent NAC treatment, however, very large numbers of par-
ticipants would be required. Nevertheless a safer infusion
causing fewer severe ADRs would also benefit patients
and health care workers, freeing their time from managing
the high frequency ADRs associated with paracetamol
overdose and its treatment.
Design and conduct of this randomised controlled trial
was associated with a number of problems, both ethical
and practical. Patients with self-harm are a potentially
challenging group to recruit into a clinical trial. We had
undertaken a survey of our patients with paracetamol
poisoning in Edinburgh prior to undertaking the study
in order to assess their views on being approached for
consent, and the need for additional blood sampling.
Many of these patients had received NAC in the past
and were therefore aware of the adverse effects caused.
Patients being treated with acetylcysteine in Edinburgh
were approached to seek their views about whether
they would wish to take part in a clinical trial involving
the modified acetylcysteine regime. They were given a
1-page summary of the research, asked about their wil-
lingness to participate and their views about consent. Pa-
tients overwhelmingly thought the research would be
useful and they would be willing to take part. With
regards to consenting procedures, if they were unable to
give informed consent, most preferred that, if a relative
did not accompany them, the decision to involve them
in the study were taken by the treating clinician. We
therefore adopted the policy that ethics consent would
not be sought from relatives by telephone, but only from
relatives accompanying the patient and therefore al-
ready aware of their presentation. We also considered
the use of an alternative personal legal representative,
proposing the senior nurse in the hospital, but the eth-
ics committee felt this was also unacceptable. This re-
sulted in a reduction in the number of potential recruits
into the study.
As detailed in the section on study amendments, we
originally believed that most patients would take para-
cetamol overdose over a period of less than an hour. It
quickly became clear that many of our patients, even
though they took their tablets at one sitting, took these
over longer than the hour originally specified in the trial
documentation. We believe this is a novel finding and
may explain some of the difficulties reported in using
paracetamol nomograms, particularly if blood samples
are taken around four hours after commencement of
drug ingestion. The ethics committee accepted a change
in overall ingestion time to less than two hours as
representing the time that would be used for including
patients within the trial. We also extended the inclusion
time to 36 h from ingestion to fall in line with national
advice provided by the UK National Poisons Information
Service.
Assessing severity of anaphylactoid reactions will be
based on the 5-point scale proposed by the World Al-
lergy Association (WAA) [28]. In this scale the most
severe reaction (Grade 5) is death. Although rarely
reported, death is extremely unlikely with NAC in this
study. Gastrointestinal features, including nausea, are
also included by the WAA, and it is inappropriate to in-
clude this in an antiemetic efficacy study of the current
design. We have therefore adopted a 3-grade study as-
sessment based on the WAA categories, and using organ
domains as the basis of the severity grading.
Recruitment targets were necessarily set higher than
required for the actual analysis since we had no data to
judge drop-out rates and adopted a 20% overall drop-
out as a potential worst case scenario when calculating
trial target recruitment. Sri Lankan experience suggested
actual drop-out rates might be much lower, and this as-
pect is one that will inform any future studies in this pa-
tient population [33].
If a shorter acetylcysteine regimen is to be used clinic-
ally it will be important to establish appropriate markers
to reliably inform early patient discharge. Some have
been suggested [34] but none has been tested prospec-
tively. In the present study we are addressing this using
conventional blood tests taken after 12 h of NAC thera-
py in both treatment arms, as well as measuring these
same end-points at the time of end of conventional the-
rapy (20.25 h) in all treatment groups. By using novel
markers of hepatotoxicity [29] we anticipate it may be
possible to discharge patients safely after the 12 h modi-
fied regimen, but this will need testing in a properly po-
wered study. Our trial should provide the data to allow
such a power calculation to be accurately performed.
Conclusion
In conclusion this study is the first attempt to undertake
a formal clinical trial in paracetamol poisoning in the
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UK since the 1970s. Developing clinical trial evidence in
the population of self-harm patients is important since
at present much of the management of poisoned pa-
tients is based on anecdote. These studies are potentially
difficult, and may involve very large numbers of patients
[33], but are essential if we are to make advances in the
care of this large patient population. Taken with the po-
tential for new markers that could give earlier indica-
tions of toxicity, or lack of it, the novel approach to
giving NAC appears to offer the potential for a new di-
mension to managing paracetamol overdose in future.
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